Birk Venture is making an investment in Cortendo AB. Cortendo is
biopharmaceutical company headquartered in Goteborg, Sweden.
The company is a pioneer in the field of cortisol inhibition and has completed
clinical trials in patients with Type 2 diabetes. The development of the lead
drug candidate Normocort (COR-003), the 2S, 4R-enantiomer of
ketoconazole, was re-directed during 2012 to Cushing’ syndrome, an orphan
disease. Normocort has received regulatory clearance by the US Food and
Drug Administration (FDA) to initiate a pivotal phase 3 trial as an
investigational new drug for Cushing’ Syndrome.